Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone734-369-2555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM."
How were Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings last quarter?
When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date?
What is the consensus analysts' recommendation for Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Has Zomedica Pharmaceuticals Corp (NYSEAMERICAN) been receiving favorable news coverage?
News coverage about ZOM stock has been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) earned a news impact score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).
Who are some of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key competitors?
Some companies that are related to Zomedica Pharmaceuticals Corp (NYSEAMERICAN) include Arcturus Therapeutics (ARCT), Hookipa Pharma (HOOK), Axovant Gene Therapies (AXGT), Generex Biotechnology (GNBT), Sol Gel Technologies (SLGL), REDHILL BIOPHAR/S (RDHL), Applied Therapeutics (APLT), Newron Pharmaceuticals (NWPHF), Mustang Bio (MBIO), Abeona Therapeutics (ABEO), TAIWAN LIPOSOME/S (TLC), Aldeyra Therapeutics (ALDX), Kala Pharmaceuticals (KALA), AVEO Pharmaceuticals (AVEO) and American Brivision (Holding) (ABVC).
What other stocks do shareholders of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) own?
Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the folowing people:
- Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)
- Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)
- Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)
- Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)
- Mr. Bruk Herbst, Chief Commercial Officer (Age 49)
Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s major shareholders?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.35%), Paloma Partners Management Co (0.18%) and Morgan Stanley (0.10%). Company insiders that own Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock include James Lebar and Rodney James Williams. View Institutional Ownership Trends for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).
Which institutional investors are buying Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock?
How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price today?
One share of ZOM stock can currently be purchased for approximately $0.3884.
How big of a company is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s official website?
How can I contact Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s mailing address is 100 PHOENIX DRIVE SUITE 190, ANN ARBOR MI, 48108. The company can be reached via phone at 734-369-2555 or via email at [email protected]
MarketBeat Community Rating for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE ZOM)
MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and other stocks. Vote "Outperform" if you believe ZOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
